700096Bacterial Vaccines and Therapies - Building a Product PipelineClosedGRD Proof of MarketInnovate UKAbsynth Biologics has successfully demonstrated an innovative approach for developing new antibacterial vaccines and antibodies. Absynth’s technology identifies proteins, essential for the life of bacteria that harness the immune system. To date the Company has shown its approach can protect against infections caused by a major pathogen Staphylococcus aureus (S. aureus), including antibiotic resistant variety MRSA (Methicillin Resistant S. aureus). The Absynth anti-S.aureus vaccine and antibodies are being advanced in pre-clinical development. A central aspect of the Absynth technology is the degree of conservation of these proteins across the bacterial kingdom. Consequently the same targets found in S. aureus also are present in many other bacterial pathogens. With this proprietary knowledge Absynth can rapidly initiate new vaccine and antibody programmes to develop a product pipeline. The objective of this project is to assess the broader market needs to prevent and treat bacterial infections, addressable by Absynth’s technology. With a clear understanding of unmet customer/patient needs, market size, drivers, dynamics and competition, Absynth will be able to select those opportunities to build a pipeline. Resistance to antibiotics in increasing at an alarming rate, driving the need for antibacterial vaccines and antibodies. The market for bacterial vaccines is expected to grow from $3.9 billion to $15.5 billion by 2014 and there is growing interest in anti-infective antibody products with only one, Synagis, licensed for use. There currently are no marketed S. aureus vaccines or antibodies and the sales potential is estimated to be >US $2 billion. Many other bacterial infections lack vaccines or antibodies including hospital infections cause by C. difficile, sexually transmitted diseases caused by N. gonorrhoea and community-based infections caused by E. coli. The new opportunities for Absynth are significant.